If your business reaches customers in the European Union through a website, marketplace, app or AI-enabled service, two EU regimes now demand your attention.
Can you use a famous luxury brand in an artwork or decorative object and call it parody? Sometimes. Can you use that brand to market and sell products? That is much riskier. A recent French decision, Hermès v Le Bidon Français, shows where the line can be drawn.
Changing one letter does not always create a new brand. That is the key lesson from the recent Australian Trade Marks Office decision involving GHOST and GHXST.
AI development contracts in Australia need to do more than describe the software being built. They need to deal with data, privacy, copyright, ownership, testing, security and who is responsible if the tool gets it wrong.
If your product, app or service excludes people, that may be more than an ethical issue. It may be a product weakness, a brand weakness and a missed commercial opportunity.
Some product names are more than names. Champagne. Darjeeling. Stilton. Parma. Pisco. These names point to place, reputation and authenticity. That is why geographical indications, or GIs, matter.
This Australian Made Week, we want to take a moment to celebrate the people building, creating, designing, inventing, and growing businesses right here in Australia.
Artificial intelligence is no longer a future concept in the pharmaceutical sector. It is already reshaping how new drugs are discovered, designed, tested and manufactured — and that shift is creating major opportunities for businesses working in life sciences, biotech and medical innovation.